Sustained Or Differential Release Type Patents (Class 424/468)
-
Patent number: 9663552Abstract: The invention provides a washing method for affinity chromatography in which a wash solution comprising arginine, or an arginine derivative, at pH greater than 8.0, is effective in removing impurities without the presence of a nonbuffering salt, while simultaneously increasing product concentration in the eluate and maintaining a high percent yield of recovered product.Type: GrantFiled: May 31, 2012Date of Patent: May 30, 2017Assignee: Novartis AGInventor: Achim Frauenschuh
-
Patent number: 9655998Abstract: Various aspects of the present disclosure provide compositions, coatings and implantable devices including a drug and an excipient. In certain embodiments the excipient and the drug are present at a weight ratio of between 10 to 1 and 1 to 10 drug to excipient. In certain other embodiments, the excipient and the drug form particles in which the drug is encapsulated by the excipient. Other aspects of the disclosure provide methods of manufacturing and using such compositions, coatings and implantable devices.Type: GrantFiled: August 7, 2014Date of Patent: May 23, 2017Assignee: Cook Medical Technologies LLCInventor: Colleen Gemborys
-
Patent number: 9636303Abstract: A pharmaceutical dosage form and method of using same, the pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, said dosage form containing a pharmacologically active ingredient (A); a physiologically acceptable polymer (B) obtainable by polymerization of a monomer composition comprising an ethylenically unsaturated monomer bearing an anionic functional group, in protonated form or a physiologically acceptable salt thereof; a polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g/mol, wherein the content of the polyalkylene oxide (C) is at least 20 wt.-%, based on the total weight of the dosage form; wherein the pharmacologically active ingredient (A) is present in a controlled-release matrix comprising the polymer (B) and the polyalkylene oxide (C).Type: GrantFiled: September 1, 2011Date of Patent: May 2, 2017Assignee: GRUENENTHAL GMBHInventors: Lutz Barnscheid, Sebastian Schwier, Johannes Bartholomäus
-
Patent number: 9629802Abstract: The present invention relates to an enteric coating formulation, as well as methods for preparing and using said enteric coating formulation. In particular, the invention relates to an enteric coating formulation that is made up of foodeous approved materials.Type: GrantFiled: September 15, 2014Date of Patent: April 25, 2017Assignee: Sensient Colors LLCInventor: Vic Young
-
Patent number: 9622997Abstract: Methods for treating insomnia are disclosed. The methods are directed to administering a pharmaceutically effective amount of baclofen to an individual suffering from insomnia. In addition, due to baclofen's positive effects on reducing nighttime reflux events, the present methods are directed to treating insomnia in patients that also suffer from nighttime reflux or gastroesophageal reflux disease (GERD) by administering a pharmaceutically effective amount of baclofen.Type: GrantFiled: March 13, 2013Date of Patent: April 18, 2017Assignee: Lynn Health Science Institute, Inc.Inventor: William C. Orr
-
Patent number: 9624195Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.Type: GrantFiled: December 23, 2015Date of Patent: April 18, 2017Assignee: Gilead Sciences, Inc.Inventors: Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman
-
Patent number: 9603943Abstract: A therapeutic agent delivery system formed of a specific type of poly(ester amide) (PEA), a therapeutic agent, and a water miscible solvent is described herein. A method of delivering the therapeutic agent delivery system by delivering the therapeutic agent delivery system formed of a PEA polymer, a therapeutic agent, and a water miscible solvent to a physiological environment and separating the phase of the therapeutic agent delivery system to form a membrane from the polymer to contain the therapeutic agent within the physiological environment is also described. Additionally disclosed is a kit including a syringe and a therapeutic agent delivery system within the syringe.Type: GrantFiled: June 25, 2015Date of Patent: March 28, 2017Assignee: Abbott Cardiovascular Systems Inc.Inventors: Lothar W. Kleiner, Syed Hossainy, Stephen Pacetti, Jessica DesNoyer
-
Patent number: 9592302Abstract: The invention provides a novel system of nano-assemblies and related method for delivery of therapeutic, diagnostic or imaging agent to biological sites. The compositions and methods of the invention enable the syntheses of novel polymeric nano-assemblies (nanoparticles) under non-emulsion conditions with the incorporation of hydrophobic guest molecules. The versatilities and advantages of the polymer nanoparticles of the invention include: (i) the guest molecules (e.g.Type: GrantFiled: May 22, 2012Date of Patent: March 14, 2017Assignee: University of MassachusettsInventor: Sankaran Thayumanavan
-
Patent number: 9585842Abstract: The present invention is directed to a pharmaceutical composition comprising guanfacine or a salt thereof in nanoparticle form and at least one non-pH dependent sustained release agent. The present invention further is directed to a method of producing said nanoparticles and to nanoparticles obtained by this method.Type: GrantFiled: April 28, 2014Date of Patent: March 7, 2017Assignee: SALMON PHARMA GMBHInventors: Akif Emre Tuereli, Bernd Baumstuemmler, Richard Ammer
-
Patent number: 9585873Abstract: A method is described for the treatment of systemic diseases in cats. A composition is administered to a cat, where the composition includes a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan).Type: GrantFiled: June 2, 2014Date of Patent: March 7, 2017Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Marcus Stark, Ulrike D. Sent, Ingo Lang
-
Patent number: 9549899Abstract: The present disclosure relates to pharmaceutical compositions that are abuse resistant and may also provide controlled release. The present disclosure also relates to the use of pharmaceutical compositions in the treatment of pain.Type: GrantFiled: July 1, 2013Date of Patent: January 24, 2017Assignee: EGALET LTD.Inventors: Peter Holm Tygesen, Karsten Lindhardt, Martin Rex Olsen, Gina Engslev Fischer, Jan Martin Overgard, Georg Boye, Nikolaj Skak, Torben Elhauge
-
Patent number: 9545380Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: GrantFiled: June 3, 2015Date of Patent: January 17, 2017Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Patent number: 9539328Abstract: The present disclosure provides an extended release pharmaceutical composition comprising hydrocodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.Type: GrantFiled: September 5, 2014Date of Patent: January 10, 2017Assignee: MALLINCKRODT LLCInventors: Krishna Devarakonda, Michael J. Giuliani, Vishal K. Gupta, Ralph A. Heasley, Susan Shelby
-
Patent number: 9532954Abstract: The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.Type: GrantFiled: June 18, 2014Date of Patent: January 3, 2017Assignee: COSMO TECHNOLOGIES LIMITEDInventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
-
Patent number: 9522137Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.Type: GrantFiled: December 17, 2015Date of Patent: December 20, 2016Assignee: PTC Therapeutics, Inc.Inventors: Samit Hirawat, Langdon Miller
-
Patent number: 9504640Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: GrantFiled: September 2, 2014Date of Patent: November 29, 2016Assignee: Valeant Pharmaceuticals Luxembourg S.Á.R.L.Inventors: Werner Oberegger, Fang Zhou, Paul Maes, Stefano Turchetta, Graham Jackson, Pietro Massardo, Mohammad Ashty Saleh
-
Patent number: 9505803Abstract: The invention provides a washing method for affinity chromatography in which a wash solution comprising arginine, or an arginine derivative, and a nonbuffering salt, preferably at high pH, greater than 8.0, is effective in removing impurities, such as high molecular weight species and host cell proteins, while also increasing product concentration in the eluate and maintaining a high percent yield of recovered product.Type: GrantFiled: December 17, 2010Date of Patent: November 29, 2016Assignee: Novartis AGInventors: Achim Frauenschuh, Kurt Bill
-
Patent number: 9492393Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: GrantFiled: June 3, 2015Date of Patent: November 15, 2016Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Patent number: 9492392Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: GrantFiled: June 3, 2015Date of Patent: November 15, 2016Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Patent number: 9492391Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: GrantFiled: June 3, 2015Date of Patent: November 15, 2016Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Patent number: 9492389Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: GrantFiled: June 3, 2015Date of Patent: November 15, 2016Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Patent number: 9492550Abstract: The presently disclosed and claimed inventive concept(s) relates to a polymer for enhancing drug performance and improving processability. Specifically, the polymer comprises hydroxypropyl methyl cellulose acetate succinate (HPMC-AS). On the HPMC-AS, the percentage of total succinoyl degree of substitution is less than 12% at C6-OH position and greater than 53% at C3-OH, and the percentage of total acetyl degree of substitution is greater than 32% at C6-OH position.Type: GrantFiled: February 21, 2014Date of Patent: November 15, 2016Assignee: Hercules LLCInventors: Todd A. Brugel, Tuyen T. Nguyen, Sangrama Sahoo, Divya Tewari, Yuda Zong
-
Patent number: 9486413Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: GrantFiled: June 3, 2015Date of Patent: November 8, 2016Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Patent number: 9456981Abstract: The present invention relates to stable orally disintegrating tablets of hyoscyamine or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such tablets and use thereof.Type: GrantFiled: February 13, 2015Date of Patent: October 4, 2016Assignee: Cadila Healthcare LimitedInventors: Manish Chawla, Shailesh Biradar, Ajay Kumar Sharma
-
Patent number: 9425525Abstract: The application discloses an improved interposer assembly with a molded plastic plate and stamp-formed metal contacts inserted in through passages in the plate. The contacts have redundant separate metal circuit paths extending between opposed contact points to reduce inductance and contact resistance.Type: GrantFiled: September 18, 2015Date of Patent: August 23, 2016Assignee: Amphenol InterCon Systems, Inc.Inventors: John D. Walden, James S. Hileman, Charles Sands Pickles
-
Patent number: 9408814Abstract: The present invention refers to a modified release pharmaceutical composition comprising desvenlafaxine or salts thereof, a release rate modifying system that controls the release of active agent(s) in both acidic and basic environments. A process of making and method of using the above-described composition is also disclosed.Type: GrantFiled: March 21, 2011Date of Patent: August 9, 2016Assignee: WOCKHARDT LIMITEDInventors: Girish Kumar Jain, Premchand Dalichandji Nakhat
-
Patent number: 9399013Abstract: An aqueous pharmaceutical suspension comprising: (i) at least one non-steroidal anti-inflammatory drug; (ii) an aqueous buffer system; (iii) xanthan gum; (iv) polyvinyl pyrrolidone; and (v) glycerol wherein the suspension is free from pregelatinized starch, amino polycarboxylic acid, microcrystalline cellulose, hydroxypropylmethyl cellulose, polyoxyethylene sorbitan monooleate, silicon dioxide and taste modifying agents selected from the group consisting of bulk sweeteners, intense sweeteners, flavoring agents and mixtures thereof.Type: GrantFiled: May 10, 2007Date of Patent: July 26, 2016Assignee: Norbrook Laboratories LimitedInventors: William Blakely, Louise Reynolds, Lillian Cromie
-
Patent number: 9358361Abstract: Methods, computer program products, and systems are described that include accepting an indication of a schedule for administration of a bioactive agent to an individual and presenting an indication of an artificial sensory experience at least partly based on the accepting an indication of the schedule for administration of the bioactive agent to the individual.Type: GrantFiled: February 14, 2014Date of Patent: June 7, 2016Assignee: The Invention Science Fund I, LLCInventors: Roderick A. Hyde, Muriel Y. Ishikawa, Eric C. Leuthardt, Royce A. Levien, Robert W. Lord, Mark A. Malamud, Elizabeth A. Sweeney, Lowell L. Wood, Jr., Victoria Y. H. Wood
-
Patent number: 9351937Abstract: Solid dosage formulations of nitazoxanide or a nitazoxanide analog are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analog thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analog thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided.Type: GrantFiled: July 30, 2013Date of Patent: May 31, 2016Assignee: Romark Laboratories L.C.Inventors: Jean-Francois Rossignol, Marc Ayers
-
Patent number: 9339478Abstract: A pharmaceutical composition in the form of a tablet including a first portion and a second portion, wherein said first portion includes guaifenesin having an immediate release profile and a second drug having a sustained release profile, and wherein the second portion includes guaifenesin having a sustained release profile. The second drug can be in the form of a drug-resin complex. The second drug can be either an anti-tussive or a decongestant. The drug-resin complex includes a drug complexed to an ion exchange resin. The ion exchange resin can be a polystyrene sulfonate resin, polacrilex resin, polacrilin potassium, cholestyramine resin, or a colestyramine resin. The drug-resin complex can be provided with a coating, the coating thickness being selected to obtain the desired release profile. The drug-resin complex can be provided with a coating level of from 5% to 50%. The coating level can be from 10% to 35%.Type: GrantFiled: February 4, 2011Date of Patent: May 17, 2016Assignee: RECKITT BENCKISER LLCInventors: Nils Ahlgren, Mark Nuttall, Jeannie Wong, Venkatesh Balasubramanian, Craig Belongie, Ashfaq Khan, Neil Campbell Muir
-
Patent number: 9308197Abstract: A pharmaceutical composition for prophylaxis or treatment of systemic diseases in cats, wherein the composition comprising administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat in need of such a treatment.Type: GrantFiled: March 13, 2013Date of Patent: April 12, 2016Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Marcus Stark, Ulrike D Sent, Ingo Lang
-
Patent number: 9303067Abstract: A pharmaceutical composition for parenteral administration of a somatostatin analog salt of aspartate, e.g. mono- or diaspartate, lactate, succinate, e.g. mono- or disuccinate, acetate, glutamate, e.g. mono- or diglutamate or citrate and water forming a gelling depot system after injection in contact with the body fluid.Type: GrantFiled: April 30, 2014Date of Patent: April 5, 2016Assignee: Novartis AGInventor: Olivier Lambert
-
Patent number: 9301966Abstract: The present disclosure relates to nutritional composition(s) comprising a carbohydrate source, a protein source, a fat source and magnesium threonate. Magnesium threonate may provide neurological health benefits when consumed. The disclosure further relates to methods of promoting neurological health by providing a nutritional composition comprising magnesium threonate. Additionally, the disclosure relates to methods of promoting GI tolerance in a pediatric subject by providing a nutritional composition comprising magnesium threonate.Type: GrantFiled: January 11, 2013Date of Patent: April 5, 2016Assignee: Mead Johnson Nutrition CompanyInventor: Brian Berg
-
Patent number: 9296739Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.Type: GrantFiled: April 4, 2014Date of Patent: March 29, 2016Assignee: Auspex Pharmaceuticals, Inc.Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
-
Patent number: 9283189Abstract: Disclosed is a sustained-release preparation of ivabradine or pharmaceutically acceptable salts thereof. The preparation contains ivabradine or pharmaceutically acceptable salts thereof and a sustained-release framework material, wherein the sustained-release framework material is selected from polyoxyethylene, or a mixture of polyoxyethylene and polyvinyl acetate or polyvinyl pyrrolidone.Type: GrantFiled: June 18, 2012Date of Patent: March 15, 2016Assignee: Jiangsu Hengrui Medicine Co., Ltd.Inventors: Kai Liu, Yuxia Wu
-
Patent number: 9283214Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.Type: GrantFiled: May 5, 2015Date of Patent: March 15, 2016Assignee: Ironshore Pharmaceuticals & Development, Inc.Inventors: David Lickrish, Feng Zhang
-
Patent number: 9278076Abstract: A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a surfactant and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core.Type: GrantFiled: March 2, 2009Date of Patent: March 8, 2016Assignee: Endo Pharmaceuticals Inc.Inventors: Anand R. Baichwal, Paul Woodcock, Steve Labudzinski
-
Patent number: 9278080Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: GrantFiled: April 27, 2010Date of Patent: March 8, 2016Assignee: Vecta, Ltd.Inventors: Aleksey Kostadinov, Ayelet David, Sabina Glozman
-
Patent number: 9265720Abstract: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.Type: GrantFiled: October 26, 2005Date of Patent: February 23, 2016Assignee: Orexo ABInventors: Anders Pettersson, Christer Nyström, Susanne Bredenberg
-
Patent number: 9259394Abstract: A dosage form comprising a tablet core containing at least one active ingredient and having at least one modified release coating that partially surrounds the tablet core is disclosed. The tablet core is preferably in the form of a compressed core wherein the at least one modified release coating is provided on a position of the exterior surface of the compressed core using dipping technology. The invention also relates to a method of manufacturing the dosage form and a method of treatment using the dosage form.Type: GrantFiled: December 7, 2010Date of Patent: February 16, 2016Assignee: Johnson & Johnson Consumer Inc.Inventors: Saumitra Bagchi, Murali Vuppala
-
Patent number: 9233959Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.Type: GrantFiled: September 8, 2014Date of Patent: January 12, 2016Assignee: Auspex Pharmaceuticals, Inc.Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
-
Patent number: 9226944Abstract: An herbal preparation for relief of sleep apnea contains lobelia and/or lobelia extract material acting as a respiratory stimulant in combination with meadowsweet to reduce nausea. Optional but preferred materials also include thyme to increase pleural activity, together with chamomile and cramp bark to facilitate relaxation.Type: GrantFiled: July 20, 2009Date of Patent: January 5, 2016Inventor: Steven R. Frank
-
Patent number: 9220686Abstract: A multiparticulate dosage form includes a plurality of individual spheroidal enteric coated particulates having (a) a diameter of 0.1 to 2.5 mm; (b) a solid core containing an effective amount of a combination of an L-menthol source and a terpene-based essential oil; (c) a continuous proteinaceous subcoating over the core; and (d) an enteric coating over the subcoating. The multiparticulate dosage form can be used to treat gastrointestinal disorders.Type: GrantFiled: November 7, 2014Date of Patent: December 29, 2015Assignee: Zx Pharma, LLCInventors: Syed M. Shah, Fred Hassan, Daniel Hassan, Sarah Hassan
-
Patent number: 9216176Abstract: A pharmaceutical composition may include a coated particulate which may include at least one active pharmaceutical ingredient, particularly one susceptible to abuse by an individual. The coated particles may include a fat/wax and have improved controlled release and/or crush resistance. Method of making these coated particulate and dosage forms therewith are also described.Type: GrantFiled: May 18, 2015Date of Patent: December 22, 2015Assignee: Cima Labs Inc.Inventors: Walid A. Habib, Ehab Hamed, Manuel A. Vega Zepeda
-
Patent number: 9211264Abstract: The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors.Type: GrantFiled: August 29, 2013Date of Patent: December 15, 2015Assignee: WYETH LLCInventors: Sripriya Venkata Ramana Rao, Syed Muzafar Shah, Christopher Richard Diorio, Maja Vencl-Joncic, Eugene Murphy
-
Patent number: 9205048Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: GrantFiled: February 10, 2015Date of Patent: December 8, 2015Assignees: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
-
Patent number: 9198904Abstract: The present invention relates to a pharmaceutical composition for oral administration comprising a modified release portion containing tamsulosin or a pharmaceutically acceptable salt thereof, and an immediate release portion containing solifenacin or a pharmaceutically acceptable salt thereof and a hydrophilic substance. In the pharmaceutical composition, the dissolution rate of each drug (in particular, solifenacin contained in the immediate release portion) is similar to those of the current single drug formulations, and the maximum percentage of drag dissolution of each drug (in particular, solifenacin contained in the immediate release portion) is 90% or more. Therefore, the pharmaceutical composition is a single formulation (i.e., a combined formulation) with a bioavailability equivalent to those of the current single drug formulations.Type: GrantFiled: February 2, 2010Date of Patent: December 1, 2015Assignee: ASTELLAS PHARMA INC.Inventors: Takehiko Yasuji, Noriyuki Kinoshita, Hiroyuki Yoshino, Shuuya Kawahama, Kazuhiro Sako, Akio Sugihara
-
Patent number: 9192577Abstract: The invention provides a novel pharmaceutical composition comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base characterized in that the acid respectively base:drug compound ratio is at least 1:1 by weight.Type: GrantFiled: November 25, 2003Date of Patent: November 24, 2015Assignee: Janssen Pharmaceutica NVInventors: Roger Petrus Gerebern Vandecruys, Jozef Peeters, Marcus Eli Brewster
-
Patent number: 9186359Abstract: The present invention relates to the use of 5-HT1 agonists in pharmaceutical compositions, compounds and methods for treatment of movement disorders related to neurological dysfunctions. The invention is particularly relevant for treatment of patients suffering from tardive dyskinesia, Parkinson's disease and associated disorders thereof. Kits of parts comprising the 5-HT1 agonist compounds or pharmaceutical compositions according to the present invention, as well as methods of preparation are also provided by the present invention.Type: GrantFiled: October 13, 2011Date of Patent: November 17, 2015Assignee: Contera Pharma ApSInventors: John Bondo Hansen, Mikael S. Thomsen
-
Patent number: 9185931Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and a mouth-soluble binder dispersed in the mouth-stable polymer matrix.Type: GrantFiled: May 12, 2014Date of Patent: November 17, 2015Assignee: Altria Client Services Inc.Inventors: Feng Gao, Frank Scott Atchley, Gregory James Griscik, Christopher Joseph DiNovi, Phillip M. Hulan, Diane L. Gee, Jason Flora, Shuzhong Zhuang